knowledge -WSS

knowledge

author：focus 2025-10-02 00:52:46 - browse：751

Illustration oh researchers look up at a blister pill pac. Part of the blister pack is filled with pills, while the center shows a sketch of a brain. -- biotech coverage from STAT — Mike Reddy for STAT

One by one, the companies behind Zoloft, Prozac, and Paxil soured on psychiatry.

It was the early 2000s, and as America warmed to the sounds of Sisqó and Shakira, the world’s largest pharmaceutical firms were running out of ideas to treat mental illness. Their blockbuster treatments for depression and schizophrenia had reshaped society and made billions of dollars in the process, but the old cash cows were soon to go generic. Efforts to one-up the last generation of drugs mostly resulted in incremental changes to aging medicines. And when insurance companies balked at paying brand-name prices for extended-release generics, the money dried up and the industry moved out.

“The mindset of Big Pharma in those days was one pill for millions and millions of people,” said John LaMattina, who led Pfizer’s research division from 1999 to 2007. “Everyone was looking for the next Lipitor, and when that fizzled out, there was an exodus out of psychotherapeutic areas.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Merck drug for rare lung condition set for approval in U.S.

hotspot

WSS

Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

Surge of respiratory disease in China has likely explanation

Readout Newsletter: Cardior, Regeneron, Nuvation, Dyne and more

Readout LOUD podcast: A CRISPR milestone, biotech mixology

Merck drug for rare lung condition set for approval in U.S.

Readout LOUD podcast: mifepristone case, GLP

hotspot

knowledge

entertainment

Malaria cases in Florida and Texas: Here’s what you need to know

World's first CRISPR

Dobbs anniversary: the lost opportunity of abortion as health care

FDA's naming rule on biosimilars has undermined competition

Virginia high school admissions case could be legal follow

The Readout: Lenmeldy, GLP

Walensky prepares to leave CDC — and Congress — behind

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

Medical records are filled with copy

There's no autism epidemic. It's an autism diagnosis epidemic

Wikipedia

A daunting task: navigating dual Medicare, Medicaid eligibility

Donor acceptance rates hint at racial, gender bias in heart transplants: study

There's no autism epidemic. It's an autism diagnosis epidemic

The Readout: Lenmeldy, GLP

Merck drug for rare lung condition set for approval in U.S.

Abortion pill Supreme Court ruling could impact entire drug industry

Wikipedia

hotspot

focus

knowledge